White Book - Celgene: An Abundance of Revlimid Opportunities in Myeloma, But Maintenance Is the Biggest Driver
Guardado en:
| Formato: | Electrónico Revista |
|---|---|
| Lenguaje: | Inglés |
| Publicado: |
Bernstein Global Wealth Management
|
| Materias: | |
| Acceso en línea: | Available in Business Source Complete. |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
Ejemplares similares
- White Book - Biotechnology: Wake Me When September Ends
- White Book - Global Biotechnology & Pharmaceuticals: ASCO 2006 Highlights
-
Biosimilars Case Study (Sandoz, Neose Technology & SciGen): Exploiting Opportunities in Biosimilars
Publicado: (2008) - Black Book - Multiple Myeloma: Patients, Penetration Price & Duration Offer Upside for Celgene Through 2015
- Black Book - Amgen & Genetics Institute: Delivering on Biotechnology's Promise (1980)